R. Stephanie Huang, PhD
Distinguished McKnight Professor and Associate Department Head, Department of Experimental and Clinical Pharmacology (ECP)
Contact
Email
Office Phone
Office Address
B-138 Phillips-Wangensteen Building
Minneapolis, MN 55455
United States
Lab Address
B-150 PWB
Minneapolis, MN 55455
United States
Links:
Titles
Professor, Department of Experimental and Clinical Pharmacology (ECP)
Associate Department Head, Department of Experimental and Clinical Pharmacology (ECP)
Associate Director, Institute of Personalized Medicine
Co-Chair, Genetic Mechanism Program within the Masonic Cancer Center
Faculty, MS and PhD Programs in Molecular Pharmacology and Therapeutics (MPaT)
Faculty, MS and PhD Programs in Bioinformatics & Computational Biology (BICB)
Education
PhD Clinical Pharmacy, Department of Pharmacy Practice, Purdue University, IN
MS Clinical Pharmacy, Department of Pharmacy Practice, Purdue University, IN
BS Pharmacy, School of Pharmacy, Shanghai Medical University, Shanghai, P.R. China
Fellowships
Clinical Pharmacology and Pharmacogenomics, University of Chicago, IL
Academic Interests
Pharmacogenomics
Biography
Bio Summary
Dr. R. Stephanie Huang is a Tenured Professor at the Department of Experimental and Clinical Pharmacology, University of Minnesota. She is also an Associate Director for the Institute of Personalized Medicine and a Co-Chair of the Genetic Mechanism Program within the Masonic Cancer Center at the University of Minnesota. She is a Chair of the International Pharmaceutical Federation (FIP) Special Interest Group on Personalised and Precision Medicine and a Chair for the Oncology Special Interest Group within the Pharmacogenomics Global Research Network (PGRN). She serves on the editorial board of Annals of Translational Medicine and Frontiers in Pharmacology. To date, she has published over 100 peer-reviewed research papers many of which are in high caliber journals, e.g., Nature, Nature Medicine, PNAS, Blood, Cancer Research, Genome Biology and American Journal of Human Genetics. Dr. Huang is a board certified clinical pharmacologist with extensive training in genetics, molecular and cell biology, clinical trials and high throughput data analysis.
Expertise
pharmacogenomics, cancer chemotherapy, miRNA, computational biology
Awards & Recognition
- 2006 Aflac Scholar-in-Training Award for American Association of Cancer Research (AACR) Molecular Diagnostics Meeting
- 2006 Awardee of 2007 Charles Huggins lecture series
- 2006 Cold Spring Harbor Laboratory Pharmacogenomics meeting Travel Award
- 2007 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Presidential Trainee Award
- 2007 American Association of Cancer Research (AACR) Merck Scholar-in-Training Award
- 2007 First place poster presentation in the Midwest Symposium on Computational Biology and Bioinformatics (MSCBB)
- 2008 Nominated for the “Future Leaders, New Directions” symposium at the 2008 AACR Annual meeting by the University of Chicago Cancer Research Center
- 2008 Cold Spring Harbor Laboratory Pharmacogenomics meeting Travel Award
- 2010, 2011 Combined Annual meeting of Central Society of Clinical Research (CSCR) and Midwestern Section American Federation for Medical Research (MWAFMR) Travel Award and K grant Award
- 2012 The first recipient of the CSCR Featured New Investigator Award
- 2012 ASCO Markers in Cancer 2012 Diagnostic Development Tutorial: Developing Biomarkers from Discovery to Oncology Practice: From Hypothesis to Product Travel Grant Award
- 2013 University of Chicago Department of Medicine (DOM) Research Day Best in Show Faculty award
- 2013 Central Society of Clinical and Translational Research CSCTR Outstanding Young Investigator Award and K award
- 2014 CSCTR K award
- 2015 Member of the Month from ASCPT (January, 2015)
- 2015 American Federation for Medical Research (AFMR) Scholar award (April 2015)
- 2018 PGRN January Featured Investigator
- 2019 7th annual University of Chicago Clinical Pharmacology and Pharmacogenomics Fellow’s Choice Lecture speaker
- 2019-20 University of Minnesota Northern LITeS cohort leadership training
- 2020 University of Minnesota CTSI Mentor of the Year nomination
- 2021 University of Minnesota COGS Outstanding advisor award
Professional Associations
American Association for Cancer Research (AACR), American Society of Human Genetics (ASHG), American Society for Clinical Pharmacology and Therapeutics (ASCPT)
Languages
- Chinese
- English
Research
Research Interests
Pharmacogenomics and computational biology
Research Methods/Techniques
computational biology, genome-wide analysis, molecular biology and cell biology
Teaching Areas
pharmacogenetics and pharmacogenomics
Publications
2023
Shan, Y., Cheung, L., Zhou, Y., Huang, Y., & Huang, R. S. A Systematic Review on Sex Differences in Adverse Drug Reactions Related to Psychotropic, Cardiovascular, And Analgesic Medications. Frontiers in Pharmacology, 14, 1082.
Zhang W, Lee AM, Jena S, Huang Y, Ho Y, Tietz KT, Miller CR, Su MC, Mentzer J, Ling AL, Li Y, Dehm SM, Huang RS. Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling. Proc Natl Acad Sci U S A. 2023 Apr 25;120(17):e2218522120. doi: 10.1073/pnas.2218522120. Epub 2023 Apr 17. PMID: 37068243.
Huang, Y., Shan, Y., Zhang, W. et al. Deciphering genetic causes for sex differences in human health through drug metabolism and transporter genes. Nat Commun 14, 175 (2023).
2021
Lee AM, Ferdjallah A, Moore E, Kim DC, Nath A, Greengard E, Huang RS. Long Non-Coding RNA ANRIL as a Potential Biomarker of Chemosensitivity and Clinical Outcomes in Osteosarcoma. International Journal of Molecular Sciences. 2021; 22(20):11168.
Gruener RF, Ling A, Chang YF, et al. Facilitating Drug Discovery in Breast Cancer by Virtually Screening Patients Using In Vitro Drug Response Modeling. Cancers (Basel). 2021;13(4):885. Published 2021 Feb 20. doi:10.3390/cancers13040885
Huang Y, Ling A, Pareek S, Huang RS. Oncogene or tumor suppressor? Long noncoding RNAs role in patient's prognosis varies depending on disease type. Transl Res. 2021;230:98-110. doi:10.1016/j.trsl.2020.10.011
2020
Ling, A., Huang, R.S. Computationally predicting clinical drug combination efficacy with cancer cell line screens and independent drug action. Nat Commun 11, 5848 (2020).
2019
Pareek S, Nath A, Huang RS. MicroRNA targeting energy metabolism in ovarian cancer: a potent contender for future therapeutics. Ann Transl Med 2019;7(Suppl 8):S299. doi: 10.21037/atm.2019.11.15
Aritro Nath, Jeremy Chang, R Stephanie Huang, iMIRAGE: An R package to impute microRNA expression using protein-coding genes, Bioinformatics, btz939
MP. Menden, D Wang, MJ. Mason, B Szalai, KC. Bulusu, Y Guan, T Yu, J Kang, M, R Wolfinger, T Nguyen, M Zaslavskiy, AstraZeneca-Sanger Drug Combination DREAM Consortium (Nath A, Huang RS), In Sock Jang, Z Ghazoui, ME Ahsen, R Vogel, EC Neto, T Norman, EK.Y. Tang, MJ. Garnett, GY. Di Veroli, S Fawell, G Stolovitzky, J Guinney, JR. Dry & J Saez-Rodriguez. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. Nature Communications. 2019. 10(1): 2674. PMID: 31209238.
Li Zhuliu, Zhang Wei, Huang RS, and Kuang Rui. Learning a Low-rank Tensor of Pharmacogenomic Multi-relations from Biomedical Networks. Accepted by 18th IEEE International Conference on Data Mining (ICDM 2019). 2019
Nath A, Lee Adam, Lau Eunice, Geeleher Paul, Cho William S, and Huang RS. Discovering novel long non-coding RNA predictors of anticancer drug sensitivity beyond protein-coding genes. PNAS. 2019. 116(44): 22020-22029. PMID: 31548386.
Aritro Nath & R. Stephanie Huang; Emerging role of long non-coding RNAs in cancer precision medicine, Molecular & Cellular Oncology, doi: 10.1080/23723556.2019.1684130
Aritro Nath, Paul Geeleher, R Stephanie Huang; Long non-coding RNA transcriptome of uncharacterized samples can be accurately imputed using protein-coding genes, Briefings in Bioinformatics, , bby129
2018
Zhou S, Skaar DJ, Jacobson PA, Huang RS. Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit. Frontiers in Pharmacology.
Ling A., Gruener R.F., Fessler J., Huang R.S. (2018). More than fishing for a cure: The promises and pitfalls of high throughput cancer cell line screens. Pharmacol. Ther. doi: 10.1016/j.pharmthera.2018.06.014.
Geeleher P., Nath A., Wang F., Zhang Z., Barbeira A.N., Fessler J., Grossman R.L., Seoighe C., Stephanie Huang R. (2018). Cancer expression quantitative trait loci (eQTLs) can be determined from heterogeneous tumor gene expression data by modeling variation in tumor purity. Genome Biol. doi: 10.1186/s13059-018-1507-0.
2017
Nath, A., Wang, J., and Huang, R.S. (2017). Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia. Mol. Diagn. Ther. 21, 621–631.
Geeleher, P., Zhang, Z., Wang, F., Gruener, R.F., Nath, A., Morrison, G., Bhutra, S., Grossman, R.L., and Huang, R.S. (2017). Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies. Genome Res. 27, 1743–1751.
Geeleher, P., and Huang, R.S. (2017). Exploring the Link between the Germline and Somatic Genome in Cancer. Cancer Discov. 7, 354–355.
Geeleher, P., Nath, A., and Huang, R.S. (2017). Institutional Profile: Pharmacogenomic research in R Stephanie Huang Laboratory. Pharmacogenomics 18, 519–522.
2016
Wang F, Chang JT, Kao CJ, Huang RS. High expression of miR-532-5p, a tumor suppressor, leads to better prognosis in ovarian cancer both in vivo and in vitro. Mol Cancer Ther. 2015.15:0943. doi: 10.1158/1535-7163.
Gladys Morrison, Divya Lenkala, Bonnie LaCroix, Dana Ziliak ,Ingrid A. Mayer, Phuong Khanh Morrow, Andres Forero, Catherine Van Poznak, Hope S Rugo, Rita Nanda, Peter H. O’Donnell, and Huang RS. Utility of patient-derived lymphoblastoid cell lines as an ex vivocapecitabine sensitivity prediction model for breast cancer patients. Oncotarget. 2016. 7(25):38359-38366. PMID: 27224917.
Michael A. Grassi, Vidhya Rao, Siquan Chen, Dingcai Cao, Xiaoyu Gao, Patricia A. Cleary, Huang RS, Jalees Rehman, Timothy S. Kern, Yoav Gilad, Nancy J. Cox. Lymphoblastoid cell lines as a tool to study inter-individual differences in the response to glucose. Accepted by PLoS One, 2016.
Geeleher, P., Cox, N.J., and Huang, R.S. (2016). Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models. Genome Biol. 17, 190.
Geeleher P, Gamazon ER, Seoighe C, Cox NJ and Huang RS. Consistency in large pharmacogenomic studies. Nature. 2016. 540 (7631):E1-E2.
Chang JT, Wang F, Chapin W, Huang RS. Identification of microRNAs as breast cancer prognosis markers through the Cancer Genome Atlas. PLoS One. 2016. 11(12):e0168284. PMID: 27959953.
2015
Chapin WJ, Lenkala D, Mai Y, Mao Y, White SR, and Huang RS. Peripheral blood IRF1 expression as a marker for glucocorticoid sensitivity. Pharmacogenetics and Genomics, 2015. 25(3): 126-133. PMID: 25564375. PMCID: PMC4315702.
Lenkala D, Gamazon ER, LaCroix B, Im HK, and Huang RS. MicroRNA biogenesis and cellular proliferation. Translational Research. 2015. Epub ahead of print. PMID: 25724890.
Geeleher P, Andrey Loboda, Divya Lenkala, Fan Wang, Bonnie LaCroix, Sanja Karovic, Jacqueline Wang, Michael Nebozhyn, Michael Chisamore, James Hardwick, Michael L. Maitland and Huang RS. Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. JNCI J Natl Cancer Inst 2015; 107 (11): djv247. doi: 10.1093/jnci/djv247
Delaney Christopher, Samuel Frank, and Huang RS. Pharmacogenomics of EGFR-Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC): EGFR and Beyond. Chinese Journal of Cancer. 2015. 34(1): 7. PMID: 25962919.
Chang JT, Lee YM, and Huang RS. The impact of the Cancer Genome Atlas on lung cancer. Translational Research 2015. 166(6):568-85. doi: 10.1016/j.trsl.2015.08.001.
2014
Grassi M., Rao V, Winkler KP, Zhang W, Bogaard JD, Chen SC, LaCroix B, Lenkala D, Rehman J, Malik AB, Cox NJ, and Huang RS. Genetic Variation is the Major Determinant of Individual Differences in Leukocyte Endothelial Adhesion. PLoS One, 2014. 9(2): e87883. PMID: 24520339. PMCID: PMC3919726.
Geeleher P, Cox NJ, and Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biology, 2014. 15(3):R47. PMID: 24580837. PMCID: PMC4054092.
Lenkala D, LaCroix B, Gamazon ER, Im HK, and Huang RS. The impact of microRNA expression on cellular proliferation. Human Genetics. 2014. 133(7): 931-938. PMID: 24609542.
Weng LM, Ziliak D, LaCroix B, Geeleher P, and Huang RS. Integrative “omic” analysis for tamoxifen sensitivity through cell based models. PLoS One. 2014. 9(4): e93420. PMID: 24699530. PMCID: PMC3974759.
Wheeler HE, Aquino-Michaels K, Gamazon ER, Trubetskoy V, Dolan ME, Huang RS, Cox NJ and Im HK. Poly-Omic Prediction of Complex Traits: OmicKriging. Genetics Epidemiology. 2014. 38(5): 402-415. PMID: 24799323. PMCID: PMC4072756.
LaCroix B, Gamazon ER, Lenkala D, Im HK, Geeleher P, Ziliak D, Cox NJ and Huang RS. Integrative analyses of genetic variation, epigenetic regulation, and the transcriptome to elucidate the biology of platinum sensitivity. BMC Genomics. 2014. 15(1):292. PMID: 24739237. PMCID:PMC3996490.
Wu KH, Gamazon ER, Im HK, Geeleher Paul, White S, Solway J, Clemmer G, Weiss ST, Tantisira K, Ratain MJ and Huang RS. Genome-wide interrogation of longitudinal FEV1 in children with asthma. Am J Respiratory and Critical Care Medicine. 2014. 190(6): 619-627. PMID: 25221879. PMCID: PMC4214107.
Geeleher P, Cox NJ, and Huang RS. pRRophetic: An R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One, 2014. 9(9):e107468. PMID: 25229481. PMCID: PMC4167990.
Bhutra S, LaCroix B, Lenkala D, Ye M, and Huang RS. Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line. PLoS One, 2014. 9(12):e115003. PMID: 25506832.
Kehua Wu, R. Stephanie Huang, Larry House and William CS Cho. Next generation sequencing for lung cancer. Chinese translated version. Zhongguo Gei Ai Za Zhi. 2014. 17(1):C1-C12. PMID: 24398316.
Rose Maimon, Kostyanovskaya Elina, and Huang RS. Pharmacogenomics of Cisplatin Sensitivity in Non-Small Cell Lung Cancer. Genomics, Proteomics & Bioinformatics. 2014. 12(5): 198-209. PMID: 25449594. PMC 4411417.
2013
Paul Geeleher, R. Stephanie Huang, Eric R. Gamazon, Aaron Golden and Cathal Seoighe. The regulatory effect of miRNAs is a heritable genetic trait in humans. BMC Genomics, 2013; 13:383. PMID: 23272639. PMCID: PMC3532363.
Jiangfang Lian, Yi Huang, R. Stephanie Huang, Limin Xu, Yanping Le, Xi Yang, Weifeng Xu, Xiaoyan Huang, Meng Ye, Jianqing Zhou and Shiwei Duan. Meta-analyses of four eosinophil related gene variants in coronary heart disease. J Thromb Thrombolysis. 2013; 36(4): 394-401. PMID: 23328882.
LN Zhang, PP Liu, Jianqing Zhou, R. Stephanie Huang, F Yuan, LJ Fei, Yi Huang, L Xu, LM Hao, XJ Qiu, Yanping Le, Xi Yang, Weifeng Xu, Xiaoyan Huang, Meng Ye, Jiangfang Lian, Shiwei Duan. Positive correlation between variants of lipid metabolism-related genes and coronary heart disease. Mol Med Rep. 2013; 8(1):260-266. PMID: 23653095. PMC3724684.
Liming Weng, Dana Ziliak, Hae Kyung Im, Eric R. Gamazon, Santosh Philips, Anne T. Nguyen, Zeruesenay Desta, Todd C. Skaar, David A. Flockhart, and R. Stephanie Huang. Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation. Annals of Oncology. 2013; 24(7): 1867-1873. PMID: 23508821. PMCID:PMC3690911.
Eric Gamazon, R. Stephanie Huang, M. Eileen Dolan, Nancy Cox and Hae Kyung Im. Integrative Genomics: Quantifying significance of phenotype-genotype relationships from multiple sources of high-throughput data. Front Genet. 2013; 3:202. PMID: 23755062. PMCID: PMC3668276.
Eric Gamazon, Federico Innocenti, Rongrong Wei, Libo Wang, Min Zhang, Snezana Mirkov, Jacqueline Ramirez, R. Stephanie Huang, Nancy Cox, Mark Ratain and Wanqing Liu. A genome-wide integrative study of microRNAs in human liver. BMC Genomics. 2013; 14(1):395. PMID: 23758991. PMC3710218.
Jianqing Zhou, Limin Xu, R. Stephanie Huang, Yi Huang, Yanping Le, Danjie Jiang, Yang Xi, Weifeng Xu, Xiaoyan Huang, Changzheng Dong, M. Ye, Jiangfang Lian, Shiwei Duan. Apolipoprotein A5 gene variants and the risk of coronary heart disease: A casecontrol study and metaanalysis. Mol Med Rep, 2013. 8(4): 1175-82. PMID: 23970179.
Xiuqin Ni, Wei Zhang and R. Stephanie Huang. Pharmacogenomics discovery and implementation in genome-wide association studies era. WIREs Systems Biology and Medicine, 2013; 5(1):1-9. PMID: 23188748.
Liming Weng, Li Zhang, Yan Peng and R. Stephanie Huang. Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics, 2013; 14(3):315-324. PMID: 23394393.
Shuangli Mi, Jian Zhang, Wei Zhang and R. Stephanie Huang. Circulating microRNAs as biomarkers for inflammatory diseases. MicroRNA, 2013; 2(1): 64-72.
Kehua Wu, R. Stephanie Huang, Larry House and William CS Cho. Next generation sequencing for lung cancer. Future Oncology, 2013; 9(9): 1323-1336. PMID: 23980680.
Jean Lee and R. Stephanie Huang. Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC inhibitor, Vorinostat. Chemotherapy, 2013; 2:111. http://dx.doi.org/10.4172/2167-7700.1000111.
Eric R. Gamazon, R. Stephanie Huang, Nancy J. Cox. SCAN: a systems biology approach to pharmacogenomic discovery. Methods Mol Biol. 2013; 1015:213-224. PMID: 23824859.